CTIS.eu › Cities › France › Dunkirk Cedex 1
Dunkirk Cedex 1
France
19 total trials
11 recruiting
2024-513889-19-00
5
Multiple Myeloma
2024-516570-30-00
4
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
2025-523117-28-00
4
Relapsed or Refractory Multiple Myeloma
2025-522109-39-00
5
2026-05-22
Alcoholic hepatitis
2025-520897-21-00
10
2026-02-25
Multiple Myeloma
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
2024-510981-18-00
5
2024-12-12
Multiple Myeloma
Multiple myeloma (MM) is a B cell malignancy and is o
2024-514099-41-00
5
2024-10-31
Alzheimer's disease
2024-514101-65-00
4
2023-12-21
Multiple Myeloma
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
2024-517215-67-00
5
2021-06-11
Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
2024-512173-27-00
5
2019-03-21
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment wi
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
2024-516168-27-00
5
2022-11-10
Adult patients with persistent or chronic immune thrombocytopenia
2024-513252-15-00
4
2021-01-28
IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
2023-509975-17-00
4
2018-04-12
Relapsed/Refractory Follicular Lymphoma
Showing 1–19 of 19 trials